Kornimate/medical-research-clean huggingface dataset:
body image disorder in anorexia nervosa and virtual reality

Conditions: Anorexia

Summary: evaluation of the tolerance and acceptability of the virtual representation of its body image.


Eligibility criteria:
inclusion criteria: * women, aged between 16 and 40 * post-puberty * pure restrictive anorexia nervosa, diagnosis by the dsm-v * bmi \<17.5 * patient attending an outpatient clinic at the bohars psychiatric hospital in france * having signed the informed consent form * for minor patients, signing the form of informed consent of both parents exclusion criteria: * associated eating disorder (bulimia, or the binge eating / purging form of anorexia nervosa), * psychiatric disorders (characterized depressed, anxiety disorder) * neurological disorders * mental retardation * abuse or addiction to alcohol * abuse or dependence on psychoactive substances in the previous year. * patient with a protective justice measure
efficacy of metformin as preventive treatment in paclitaxel induced peripheral neuropathy in breast cancer patients

Conditions: Peripheral Neuropathy; Breast Cancer

Summary: at present, there are no fda-approved treatments for chemotherapy-induced neuropathy. discrete neuro anti-inflammatory effects of metformin support its repurposing as a neuroprotective agent in patients with neurodegenerative diseases. therefore, this study aims to evaluate the effect of metformin on the amelioration of paclitaxel induced neuropathy in cancer patients.


Eligibility criteria:
inclusion criteria: * adult patients (\>18 years old) * early-stage breast cancer patients who will receive adjuvant paclitaxel * performance status according to eastern cooperative oncology group (ecog) \< 2. * adequate bone marrow function (white blood count ≥4,000/mm3, platelet count ≥100,000/mm3), liver function (serum total bilirubin \<1.5 mg/dl), renal function (creatinine\<1.5 mg/dl). exclusion criteria: * clinical neuropathy at prior to enrollment. * patients treated with medications that increase the risk of neuropathy like amiodarone, colchicine, metronidazole, phenytoin. * patients with a history of hypersensitivity to metformin. * pregnant or lactating females. * patients who are using metformin for any other cause. * patients with diabetes mellitus. * receiving vitamin b1, b6, b12 or another vitamin supplemental therapy. * receiving antidepressants, opioids, adjuvant analgesic agents (eg, anticonvulsants, clonazepam, or mexiletine), topical analgesics, and amifostine.
clinical evaluation of a new viscoelastic for cataract surgery

Conditions: Cataract

Summary: the purpose of this study is to evaluate the safety and effectiveness of a new opthalmic viscoelastic material for the use in cataract surgery. the new viscoelastic will be compared to a currently marketed viscoelastic material.


Eligibility criteria:
inclusion criteria: * otherwise healthy eye with no pathology other than the presence of cataract * visual potential of 20/40 or better exclusion criteria: * taking any medications that affect vision, intraocular pressure or ease of cataract surgery (e.g. flomax, glaucoma medications, etc.) * known intraocular pressure increases from steroid treatment * low endothelial cell count
effect of st. john's wort and olive oils on the postoperative complications

Conditions: Impacted Third Molar Tooth

Summary: surgical removal of impacted third molars is one of the most frequent procedures carried out in the oral and maxillofacial surgery clinics. there are a varying range of postoperative complications including pain, edema and swelling. antibiotics, analgesics and mouthwashes are usually prescribed for the treatment of these complications. patients undergoing impacted third molar surgery are frequently prescribed chlorhexidine mouthwashes with/without benzydamine hydrochloride. however, to preclude the adverse effects of these chemical agents, there has been a search for plant-derived alternatives with anti-inflammatory, antibacterial and analgesic properties as part of the oral care routine following surgical removal of impacted third molars. however, there is no study investigating the comparison of different essential oils in the literature. thus, this multicenter study was aimed to evaluate the effects of st. john's wort oil and virgin olive oil on the postoperative complications and compared with chlorhexidine gluconate plus benzydamine hydrochloride mouthwash after the removal of impacted wisdom teeth.this study was aimed to evaluate the effects of st. john's wort oil, virgin olive oil, and chlorhexidine gluconate plus benzydamine hydrochloride on the postoperative complications after the removal of impacted wisdom teeth.


Eligibility criteria:
inclusion criteria: * be 18-40 years old * has unilateral mandibular impacted third molars with similar angulation position according to winter's classification (mesio-angular) and similar impaction degree according to pell \& gregory's classification (class ii, level b). * absence of any systemic disease * absence of pregnancy/lactating state, exclusion criteria: * patients with smoking habits, drug abuse, history of pericoronitis associated with the lower third molar * not regularly coming to the controls
heart watch study: a pragmatic randomized controlled trial

Conditions: Cardioversion; Atrial Fibrillation

Summary: this will be a prospective multi-center, randomized, controlled trial of 150 patients conducted to assess the impact of individual use of the apple watch compared to the withings move on patient-reported and clinical outcomes at 6 months and up to 1 year.

this is a a randomized, controlled trial to determine the impact of the apple watch series 6 compared to the withings move on both patient-reported outcomes and clinical utilization over 6 months and up to 1 year. our research method will employ a patient-centered health data sharing platform (called hugo) for real-world surveillance of outcomes in 150 total patients after they receive elective direct current cardioversion (dccv) or catheter ablation for treatment of atrial fibrillation or atrial flutter. patients will be enrolled at each of 3 clinical sites: yale-new haven hospital, the mayo clinic, and duke health. half of the patients will be randomized to receive the apple watch series 6, while half will receive a control device (withings move). patients will then be queried about specific symptoms related to atrial fibrillation and medication adherence monthly. this project will provide novel and needed post-market data about the apple watch series 6 ecg and irregular rhythm detection notification features and, on a larger scale, help delineate the impact of an innovative digital health technology on real-world patient outcomes. specific aim 1: to assess the impact of using the apple watch ecg and irregular rhythm notification features on patient-reported outcomes and clinical utilization after patients receive cardioversion or catheter ablation for atrial fibrillation or atrial flutter. specific aim 2: to determine the accuracy of the apple watch ecg compared to physician interpretation of 12-lead ecgs obtained in routine clinical care.

Eligibility criteria:
inclusion criteria: * age \>22 * english-speaking * planned for direct current cardioversion or catheter ablation for atrial fibrillation or atrial flutter, as noted by referring clinical staff or on chart review * participant is willing and able to read and sign consent and participate in study * participant lives independently and does not require continuous care * participant has an email account (or is willing to create one) * participant has a compatible smartphone (iphone 6s or later) * participant is willing to wear only the device they are randomized to receive for the study period for as many hours during the day as they are able, except for time spent charging the device or in environments that may be suboptimal for the device * participant is willing to use the hugo mobile health platform and apple watch series 6 or withings move * participant has cardiology care at ynhh, duke health, or mayo clinic exclusion criteria: * no exclusion criteria
optimization of the parameters of vagal nerve stimulation

Conditions: Epilepsy

Summary: vagal nerve stimulation (vns) is one of the neuromodulation techniques that can be indicated in patients suffering from refractory epilepsies, especially when an open resection has failed or is not indicated. however to date it is not possible to predict which patients will respond and what are the best parameters of stimulation to be set (pulse width, frequency and intensity). it has been shown that responders to vns have reduced interictal cortical synchronicity on scalp eeg based on phase lag index (pli), a marker of functional connectivity (fc) the aim of this study is to test the following hypothesis: setting the parameters of stimulation on the basis of the lowest values of phase lag index (pli) obtained on scalp eeg with different settings of parameters (as compared with a randomly chosen set of commonly used parameters) will increase the rate of responders to vns.


Eligibility criteria:
inclusion criteria: * male or female epileptic patients over 12 years of age * suffering from pharmaco-resistant epilepsy * with newly implanted vns aspire sr device * surgery performed in the previous 6 months * electrode impedance should be within normal range ( \< 4000 ohms) * auto-stim mode working properly * mean number of seizures of at least (average 4 (mean value) / months during the baseline period) * patient, parents or legally representatives who have given written informed consent to allow the study data collection and procedures exclusion criteria: * difficulty to read or understand the french language, or inability to understand the information regarding the study * total patient's iq below 64 * subject in exclusion period due to enrolment in another study * patient with postoperative left vocal cord paralysis * patient on vns since more than 6 months

Keywords: epilepsy vagal nerve stimulation phase lag index
improving cognitive aptitudes with tdcs in patients with multiple sclerosis

Conditions: Relapsing Remitting Multiple Sclerosis; Secondary-progressive Multiple Sclerosis; Cognitive Deficits; Motor Deficits

Summary: noninvasive brain stimulations (nibs) will be used in ms patients with cognitive impairments to enhance their cognitive aptitudes.

tdcs will be used in a sham-controlled, double-blind, randomized, cross-over control trial in ms patients suffering from cognitive impairments and/or motor deficits. after informed consent and recruitment, patients will be randomly (computer method) allocated to real or sham tdcs, that will be applied during working memory and attentional tasks. a few days/weeks after completing one arm, the patients will enter the other arm (double-blind cross-over design). baseline and follow-up outcomes about cognitive aptitudes, motor tasks and fatigue will be collected.

Eligibility criteria:
inclusion criteria: * ms patients with relapsing remitting ms/secondary progression ms (based on the 2010 revised mcdonald criteria) * cognitive deficits * motor deficits exclusion criteria: * contraindication to tdcs (seizure or epilepsy, metal in the head, ...) * major psychiatric conditions or major depression * coexisting instable medical condition * substance or alcohol abuse * regular intake of drug that strongly modulate brain excitability * major sequels from ms preventing participation in the study * pregnancy

Keywords: multiple sclerosis ms cognitive deficits motor deficits fatigue nervous system diseases brain diseases brain stimulation working memory motor learning central nervous system diseases neuropsychological rehabilitation
dysregulation of lipid metabolism and right ventricular function in pah

Conditions: Pulmonary Arterial Hypertension

Summary: right ventricular (rv) failure is the predominant cause of death in pulmonary arterial hypertension (pah). no rv-specific therapies are available, in part because the underlying mechanisms of rv dysfunction are poorly understood. given the heart's preference for fatty acids (fa) as an energy source, a deeper understanding of fa metabolism may shed light on rv adaptation to elevated afterload in pah. the purpose of this study is to test the hypothesis that defects in fatty acid metabolism are common in pah and contribute to rv failure. the investigators will measure peripheral and transcardiac lipid and glucose metabolites in pah patients in comparison with patients with pulmonary venous hypertension and no evidence of pulmonary hypertension. the investigators will also correlate metabolites with concurrent measurement of right ventricular function.


Eligibility criteria:
inclusion criteria: * ≥ 18 years old * scheduled to undergo cardiac catheterization (right ± left heart catheterization) and/or electrophysiology study in the vhvi cardiac catheterization laboratory (ccl)/electrophysiology laboratory (ep lab) * hemoglobin value ≥ 10 g/dl or hematocrit of ≥ 30% (measured on clinically-indicated blood draw within 30 days or a point-of-care measurement in ccl/ep laboratory if clinically-indicated value is not available) exclusion criteria: * any individual that is anemic and has a hemoglobin value \< 10 g/dl and hematocrit of \< 30% will be excluded from the study. * if a physician performing the procedure believes that performing the extra steps and /or acquiring the additional blood samples will delay or otherwise compromise participants' care, he/she can abandon acquisition of those data at his/her discretion. * contraindication to cardiac mri (applies only to patients undergoing cmr as part of this protocol). * implanted ferromagnetic material * glomerular filtration rate \< 60ml/min (measured on clinically-indicated blood draw within 30 days of cmr or a point-of-care measurement in the cmr laboratory if clinically-indicated gfr is not available)
dose response study of al-37807 ophthalmic solution in patients with open-angle glaucoma or ocular hypertension

Conditions: Open-Angle Glaucoma; Ocular Hypertension

Summary: the purpose of thie study is to compare the safety and iop-lowering efficacy of al-37807 ophthalmic solution 0.05%, 0.1% and 0.2% dosed qd am to xalatan dosed qd pm and vehicle in patients with open-angle glaucoma or ocular hypertension


Eligibility criteria:
inclusion criteria: * open-angle glaucoma * ocular hypertension exclusion criteria: - va worse than 0.60

Keywords: open-angle glaucoma ocular hypertension
comparison of surgical outcomes between mpcnl and rirs

Conditions: Renal Stone

Summary: the objective of this research is to investigate the surgical outcomes of minimally invasive percutaneous nephrolithotomy(mpcnl) and retrograde intrarenal surgery (rirs)for patients with renal stone larger than 1cm.

it is pointed out that there is the disadvantage of conventional pcnl technique which showed dramatic decrease in hb and renal damage even though it has some advantages of a short operation time and a high stone-free rate. mpcnl and rirs has recently been considered as very efficacious methods.

Eligibility criteria:
inclusion criteria: * the person who has been diagnosed with renal stone larger than 1cm renal and who has been supposed to undergo mpcnl or rirs. * the person who signed up for participation and agree with intention of clinical test. exclusion criteria: * the patient whose medical record has been omitted from database. * the patient who has an anatomical abnormality of urinary tract and/or metabolic illness * the patient who do not agree with the intention of the clinical study.

Keywords: percutaneous nephrolithotomy renal calculi ureteroscopy
emotional recovery post-stroke

Conditions: Stroke; Mental Health Wellness 1

Summary: the purpose of this study is to evaluate whether adding an emotional wellness component to occupational therapy (ot) and/or speech therapy (st) telerehabilitation improves overall emotional well-being and activity participation for people with stroke.

the purpose of this study is to evaluate whether adding an emotional wellness component to occupational therapy (ot) and/or speech therapy (st) telerehabilitation improves overall emotional well-being and activity participation for people with stroke. participants will complete 9 telerehabilitation therapy sessions over 8 weeks. these sessions will take place over a video visit using a personal device (phone, tablet, or computer). each session will last about 1 hour. sessions will focus on occupational therapy and/or speech therapy depending on the participant's stroke-related movement and/or language deficits. each study participant will be randomly assigned to one of two intervention groups. both groups will include ot or st; however, one group will include an emotional wellness component using a modified version of cognitive behavioral therapy. participants will also complete 2 assessment visits, one before the telerehabilitation begins and one after the telerehabilitation program ends. the assessment visits will also take place via a video visit using a personal device. assessments include measures of emotional well-being, quality of life, activity engagement, arm/hand movement, communication/language skills, balance, and ability to perform daily activities.

Eligibility criteria:
inclusion criteria: * self-reported stroke-related deficits in emotional wellness such as anxiety, sleep disturbance, dread, fear, loss of hope, sadness. * have experienced ischemic or hemorrhagic stroke at least 30 days prior * stroke-related aphasia and/or upper extremity hemiparesis * aged 21 years or older * english as primary language * have corrected vision to be able to read text on a screen * able to participate fully in the study's tele-rehabilitation (aim 1) and/or virtual group programing (aim 2) with personally owned device (i.e., phone, tablet, or laptop) and personal wi-fi connection or cellular service * cognitive, language, and motor capacity to participate fully in the study's assessment session as per the judgment of the licensed, experienced stroke tele-rehabilitation occupational or speech therapist exclusion criteria: * unable to follow 1-2 step instructions given by the study team member during the informed consent procedures. * pain that interferes with ability to participate in the study's upper extremity movement tasks. * have impaired decision making capacity as determined by the u-are protocol for assessing capacity to provide informed consent.

Keywords: rehabilitation studies stroke stroke recovery
testing of four home phenylalanine monitoring prototype devices

Conditions: Phenylketonurias

Summary: the objective of this study is to test four home phenylalanine monitoring prototype devices, selected out of a pool of candidates by the national pku alliance scientific committee.

a real time, point-of-care and home phenylalanine monitoring system would provide patients with quick results and feedback. home monitoring devices' phenylalanine measurements will be compared to the current gold-standard measurement of phenylalanine (plasma concentration) in four subjects with pku and one control subject. the study will enroll subjects with different baseline phenylalanine concentrations (i.e., patients with poor to good metabolic control, assessed by comparing current phenylalanine concentrations to established treatment ranges). for each prototype device, three separate measurements of phenylalanine per subject will be performed. three prototype devices require whole blood, thus 1 teaspoon (approximately 4ml) of whole blood will be collected through venipuncture and blood spots will be used to conduct tests. one prototype requires capillary blood to be collected through a fingerstick, and will require three blood spots from the stick. a single plasma amino acid analysis for each participant will also be performed using leftover whole blood from the 4ml blood draw through quantitative ion exchange chromatography, reported as micromoles/l.

Eligibility criteria:
inclusion criteria: * diagnosis of pku or hyperphenylalaninemia (pku group) * any age * in good health (pku and control group) exclusion criteria: * pregnant * have any medical comorbidities * considered unfit for participation by the principal investigator
paternal age and fetal aneuploidy

Conditions: Trisomy 21

Summary: trisomy 21, commonly known as down syndrome, is the most common chromosomal abnormality in humans. advanced maternal age (ama) is a well-recognized risk factor for trisomy 21, with the risk increasing significantly beyond the age of 35. research on the effects of paternal age on the prenatal risk of trisomy 21 is lacking, with inconsistent findings in the literature. the harmony® prenatal test is an non-invasive prenatal testing (nipt) that screens maternal blood for chromosomal abnormalities in the cell-free fetal dna (cfdna). the harmony® prenatal test can detect conditions such as trisomy 13, 18, and 21, as well as sex chromosome abnormalities. the optimo test is a prenatal screening test that screens for trisomies 13, 18 and 21 in the developing fetus using extended biochemical screening in maternal. the optimo test has shown high sensitivity and specificity in detecting trisomy 21.


Eligibility criteria:
inclusion criteria: * pregnant women aged 18 years or older (at the time of trisomy 18 and 21 screening) and who were able to complete the questionnaire in either french or english * pregnant women who completed the entire trisomy 21 screening process at clinique ovo were included exclusion criteria: * patients who did not indicate the male partner/donor's age were excluded * patients who did not complete or sign the clinical information form
evaluation of the minimalist music and birdsongs in the anxiety of nursing professionals in oncology

Conditions: Anxiety Disorders and Symptoms

Summary: this project aims to investigate the effects of an intervention involving minimalist piano music and bird singing on the anxiety of nursing professionals working in the oncology sector of a hospital.

the demand for care with mental health of nursing professionals is increasingly present, considering the high rate of anxiety symptoms presented by the teams providing health care within hospitals. oncology is one of the sectors where professionals have constant contact with situations of suffering and death, being a place where the enlargement of therapeutic tools for handling anxiety symptoms may bring benefits. scientific literature has never described the effectiveness of works with minimalist music and birds singing used simultaneously with anxiety relief resources. objective: assess the effects of music intervention, with minimalist repertoire, with or without association to birds singing over anxiety of nursing professionals that work in oncology. method: randomized clinical controlled trial. the study will be performed in the oncology sector of israeli hospital albert einstein located in são paulo, brazil and the population consists in 100 nursing professionals. the intervention will consist in a musical part, especially developed for this study and in recording of birds singing, played live for each one of the participants, individually with 10 to 15 minutes duration. the instrument for anxiety assessment chosen for this project is short-form of state-trait anxiety inventory (stai-s-6). the project was approved by the research ethics committee, whose identification number on plataforma brasil (caae) is 59498222.6.0000.0071

Eligibility criteria:
inclusion criteria: * nursing professionals working in oncology unit * over 18 years old exclusion criteria: * nursing professionals who, for whatever reason, are unable to fully participate of the proposed musical intervention.

Keywords: nursing professionals anxiety oncology music nature